CereVasc Alzheimer's Study Shows How an Investigational Device Exemption Works

CereVasc said on Oct. 29, 2026, that FDA has approved an investigational device exemption, or IDE, allowing the company to evaluate its eShunt System in patients with early symptomatic Alzheimer's disease, according to the Boston company's announcement. The company describes the eShunt as a minimally invasive endovascular shunt that diverts cerebrospinal fluid to the venous system, and said it will investigate whether increasing that fluid's circulation may support the brain's clearance of Alzheimer's-associated neurotoxins.

The release did not give the study's size, sites or endpoints. It said the device is investigational, has not been approved by FDA, and that its safety and effectiveness have not been established. "Receiving FDA authorization to evaluate the eShunt System in Alzheimer's disease marks an exciting chapter for CereVasc," President and Chief Executive Tony Kingsley said in the release.

An IDE approval is a step that comes before any clearance or approval. Here is what it covers.

What an IDE allows

FDA's IDE page says an approved exemption "allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data." Such studies "are most often conducted to support a PMA," the agency says.

The exemption lets the device be shipped for the study without meeting requirements that apply to commercial devices. While a device is under investigation, its sponsor does not need to have filed a PMA or 510(k) or to register and list it. The rules for device studies are in 21 CFR Part 812, which covers applications, responsibilities, labeling, records and reports.

Patient protections apply throughout. FDA says evaluating an uncleared device requires an investigational plan approved by an institutional review board, informed consent from all patients under 21 CFR Part 50, and labeling stating that the device is for investigational use only. CereVasc's website carries the required caution: "Investigational device. Limited by federal (or United States) law to investigational use."

Risk decides who signs off

Not every device study needs FDA's approval before it starts. According to FDA's IDE approval process page, a significant-risk study needs both FDA approval of an IDE and IRB approval before it begins. A nonsignificant-risk study "requires only IRB approval prior to initiation of a clinical study." Each site must have IRB approval before enrolling patients, and the FDA and IRB reviews can run at the same time.

FDA's review has a fixed clock. The agency says an IDE is "considered approved 30 days after it has been received by the FDA" unless FDA notifies the sponsor otherwise. Its decision can be approval, approval with conditions, or disapproval; a sponsor can respond to deficiencies or request a regulatory hearing.

FDA also describes early feasibility studies, "a limited clinical investigation of a device early in development," as one type of study run under an IDE.

Other studies

CereVasc said it is also evaluating the eShunt System for normal pressure hydrocephalus and recently completed enrollment in STRIDE, its pivotal trial in that condition.